The latest price target for Fulgent Genetics (NASDAQ:FLGT) was reported by Piper Sandler on November 11, 2025. The analyst firm set a price target for $30.00 expecting FLGT to rise to within 12 months (a possible 105.55% upside). 5 analyst firms have reported ratings in the last year.

The latest analyst rating for Fulgent Genetics (NASDAQ:FLGT) was provided by Piper Sandler, and Fulgent Genetics maintained their neutral rating.

The last upgrade for Fulgent Genetics Inc happened on August 5, 2025 when UBS raised their price target to $30. UBS previously had a neutral for Fulgent Genetics Inc.

There is no last downgrade for Fulgent Genetics.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Fulgent Genetics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Fulgent Genetics was filed on November 11, 2025 so you should expect the next rating to be made available sometime around November 11, 2026.

While ratings are subjective and will change, the latest Fulgent Genetics (FLGT) rating was a maintained with a price target of $21.00 to $30.00. The current price Fulgent Genetics (FLGT) is trading at is $14.60, which is out of the analyst’s predicted range.